Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Change in Receivables (2024 - 2025)

Historic Change in Receivables for ImmunityBio (IBRX) over the last 4 years, with Q3 2025 value amounting to $9.9 million.

  • ImmunityBio's Change in Receivables rose 21476.77% to $9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.8 million, marking a year-over-year increase of 56685.03%. This contributed to the annual value of $2.4 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, ImmunityBio's Change in Receivables stood at $9.9 million, which was up 21476.77% from $5.1 million recorded in Q2 2025.
  • ImmunityBio's 5-year Change in Receivables high stood at $14.7 million for Q1 2025, and its period low was -$1.8 million during Q4 2024.